肿瘤药学2016，Vol.6Issue(2)：142-145,4.DOI:10.3969/j.issn.2095-1264.2016.02.11
尿 NGAL 与 Cys-C 用于诊断多发性骨髓瘤早期肾损伤的临床价值研究
Clinical Value of uNGAL and uCys-C for Early Renal Impairment in Multiple Myeloma Patients
摘要
Abstract
Objective To discuss the diagnostic value of urinary NGAL (uNGAL) and urinary Cystatin C (uCys-C) for the early renal impairment in multiple myeloma (MM) patients. Methods According to the estimated glomerular filtration rate (eGFR), the MM patients were divided into two groups, group A (eGFR≥90 ml·min-1, n=38), the normal renal function group, and group B (eGFR<90 ml·min-1, n=34), the renal impairment group. Another 76 healthy subjects were selected as control group. The concentrations of uNGAL, uCys-C and Scr were measured and compared. Results The levels of uNGAL and uCys-C in group A were significantly higher than those in the control group (P<0.01). The levels of uNGAL, uCys-C and Scr in group B were also significantly higher than those in the control group (P<0.01). The positive rate of the combined detection of uNGAL and uCys-C was 52.38%, significantly higher than single index detection (P<0.05). Conclusion Com-pared with the traditional biomarkers, uNGAL and uCys-C were more sensitive and effective indexes for the diagnosis of early renal impairment in multiple myeloma patients. Jointed detection of the two had more important value.关键词
多发性骨髓瘤/肾损伤/中性粒细胞明胶酶相关载脂蛋白/胱抑素 CKey words
Multiple myeloma/Renal impairment/NGAL/Cys-C分类
医药卫生引用本文复制引用
袁新科,黄映红,李萌,李大勇,吴运斗,肖平..尿 NGAL 与 Cys-C 用于诊断多发性骨髓瘤早期肾损伤的临床价值研究[J].肿瘤药学,2016,6(2):142-145,4.基金项目
长沙市科技局2015年社会发展科技支撑资金资助项目（K15ZD019-33）。 （）
